Welcome everyone, and thank you for joining the meeting today. My name is Greg Batcheller. I'm the Chairman of the Board of Intellego Technologies AB. The purpose of today's call is to look at our Q4 2025 report and our restated accounts for 2024 and 2025. This is, in effect, the last act of the old Intellego board of directors, which now leaves a clean slate for the new board, which will be elected on Monday. Our team at Intellego, consisting primarily of our CFO, Henrik Resmark, and our accountant, Magnus Lundberg, supported by several others, have literally worked around the clock to get this report ready today. It has been a huge task that has had to take into account all the findings from the KPMG investigations, as well as our own internal investigations. So I acknowledge and thank them on behalf of the whole company for this important work, and I would be remiss if I did not also acknowledge and thank the KPMG forensic team and also our auditor for their work and support in this process. This report is not perfect, and you will see references in it to risks and uncertainties, but the board's judgment is that it is important to get this report into the hands of shareholders ahead of their meeting on Monday. In a minute, Henrik Resmark, our CFO, will go through some of the more important points in the report, and then Jacob Laurin, our CEO, will speak about the business of Intellego and its future. Now, I want to emphasize that the old board has not made any binding strategic decisions about the future direction of Intellego's business. That is something that is very definitely for the new board to consider and decide. But what we have done is to undertake a strategic review of our different business areas and opportunities, which can serve as a basis for the new board's deliberations and help them get up and running as quickly as possible. I can tell you that over the past three months, since Claes Lindahl was arrested, we have worked to stabilize the situation in Intellego, to understand, via KPMG's two reports on our own investigations, what has gone on with this massive fraud, to deal with the consequences, such as with this report today and the restatement of our accounts, and to reach out to our key stakeholders, including customers, collaboration partners, employees, suppliers, investors, and shareholders. The objective has been to draw a line at November 18th, 2025, to create a secure and stable situation in the company and hand over a clean slate to a new board that gives the company the best possible chance at a new start. This, we believe, is the best way that Intellego will be able to achieve its potential and return value to our shareholders and others who have been impacted by this fraud. With that, I want to turn it over to Henrik Resmark to run us through the numbers. But before I do, let me explain that it is possible to ask questions about today's presentation. There's a questions button on your screen that will enable you to send a question by email, which we will then answer by email. So, Henrik, over to you. Thanks, Greg. Hi, my name is Henrik Resmark. I joined Intellego in January this year as CFO and COO. My background is primarily a CFO for quoted companies and private equity-owned companies. First, I start with adjustments and restatements. The company portrayed in numbers here today is significantly different and smaller than the one reported in the third quarter, 2025. The financial statements for 2025 and 2024 have been adjusted, restated due to incorrect bookkeeping and accounting. We have the forensic analysis performed by KPMG and also the Intellego analysis. Based on findings, the annual accounts for 2025 and 2024 are adjusted, restated. We have made corrections. When adjusting for incorrect revenue recognition, there are several transactions that must be analyzed in depth to make these corrections. They involve the profit and loss account and the balance sheet. This has been very time-consuming, and the team has made an extraordinary effort to be able to report this fourth quarter 2025 report today. Having said that, as we state in the Q4 2025 report, there are additional investigations and analysis still ongoing over the accounts. This means that there may be additional adjustments. Such potential additional adjustments will, in such case, be presented in connection to the annual report 2025. Intellego has initiated independent forensic investigations by KPMG in order to be able to report the correct numbers. The first forensic analysis by KPMG, presented on January 30th, shows that SEK 640 million were incorrect, recognized as revenue in 2025. Basic conditions to be able to book it as revenues do not exist, lack of documentation and deliveries. Those SEK 640 million have been reversed and are all bookings connected to those bookings?... Further, the second KPMG forensic analysis regarding 2024, as of February 19th, shows the same pattern in 2024 that was detected for 2025. The conditions to recognize the revenues are not there, approximately SEK 134 million. Consequently, those revenues have been reversed and all bookings connected to that. To be clear, also, cost bookings and balance sheet items have been adjusted for. Intellego has filed a request for deferral of tax payment to the Swedish Tax Agency. The tax payment of approximately SEK 20 million, that is scheduled for March 26, relates to the pre-tax profit 2024. Intellego has reasons to believe that the tax declaration, based on the accounts and profits for the financial year 2024, is significantly overstated. The forensic analysis performed by KPMG, as mentioned, covers also 2024. Now, I move into Intellego Technologies and Intellego Group. I start with some financial information for the parent company, Intellego Technologies AB. The revenues for the fourth quarter 2025 amounts to SEK 81 thousand, compared to restated SEK 791 thousand, fourth quarter 2024. The adjusted full year revenues 2025 amounts to SEK 4.2 million versus SEK 3.9 million in 2024. The comparable figures for 2024 have also been adjusted, restated, to be able to compare 2025 with adequate numbers. Now, I move to operating profit, also called EBIT. Operating profit amounted to -96.9 million SEK in fourth quarter 2025, versus -13.5 million SEK in fourth quarter 2024. Full year 2025, the operating profit amounted to -178.5 million SEK versus 18.5 million SEK in fourth quarter 2024. The balance sheet has also been adjusted, restated for transactions that were incorrect and were related to the incorrect recognized revenues. The shareholders' equity, as per December 2025, amounts to 183 million SEK versus 103 million SEK in December 2024. The cash position amounts to approximately 51 million SEK after deduction of the seizure of cash of in total, 230 million SEK. As mentioned earlier, Intellego has filed a request for deferral of the tax payment that is due in March. This is important, and we intend to have a dialogue with the Swedish Tax Agency to try to speed up that process. As the revenues for Intellego Technologies AB are significantly lower, hence, the actual result and cash flow are lower, the cash position going forward will be negatively affected. Now, I will present some financial information for the Intellego Group. The adjusted revenues for fourth quarter 2025 amount to SEK 25.6 million, compared to SEK 21.2 million, fourth quarter 2024. The adjusted full year revenues 2025 amount to SEK 98 million versus 94 in 2024. As I mentioned, the comparable numbers for 2024 are restated. The growth are generated by the Daro Group in UK. Operating profit, fourth quarter 2025, amounted to -SEK 88 million versus -SEK 15 million in fourth quarter 2024. For full year 2025, the operating profit amounted to -SEK 175 million versus -SEK 15 million in 2024. The shareholders' equity, as per year-end, amounts to SEK 189 million versus SEK 125 million in December 2024. The cash position amounts to approximately SEK 58 million, again, after deduction of the seizure of cash of in total, SEK 230 million. We are not guiding on any financial performance 2026. The revised Intellego business plan is being produced as we speak. Then the final part from me is information regarding the Daro Group. The Daro Group is a growth business, profitable and cash generating. Intellego subsidiary, Daro Group, consists of six companies in the U.K., active within industrial lighting, UV disinfection, and contract manufacturing. Daro is not exposed to the forensic investigation that is ongoing for Intellego Technologies AB. In 2025, Daro reached revenues of GBP 7.3 million, a growth of approximately 7% versus 2024. These numbers are in local currency.... The EBITDA margin reached approximately 11%, 2025 versus 10% in 2024, and the Daro Group has approximately 53 employees. Given the findings in Intellego Technologies AB, Daro is the foundation of Intellego Group going forward. By that, I hand over to Jacob. Thank you, Henrik. My name is Jacob Laurin. I am the interim CEO since late November, and I'm also a board member since June 2024. Let me give you a short brief of how I see the standing of Intellego's business right now. Since late November, when I was put in charge, we have been spending time on analyzing what Intellego should look like going forward. What I will briefly present now is a view of our basic business, as well as some interesting projects that we have been working on since one or two years. Looking at the basic product, it is the disinfection market. There is a need worldwide for effective methods of disinfection in the healthcare sector. As the antimicrobial resistance, or the AMR, continues to rise globally, the healthcare sector is under pressure to act and deploy prevention tools that do not drive further resistance. Our analysis is that there should be a big global potential for UVC products in the market, basically because of this large risk of AMR, antimicrobial resistance. For Intellego, this opens up a global opportunity for dosimeters, especially in validating the effectiveness of the disinfection. But to capture that opportunity, we need to work very hard improving the necessity and the usefulness of dosimeters. Regulations are reinforcing this trend, and that creates opportunities for dosimeters to take a leading role. So looking ahead, Intellego's vision to be the preferred partner and supplier for dosimeters in this area, based on our patented photochromic ink technology. Another development project which we believe has good potential, the UV curing. With the upcoming need for industrial sector, UV curing. UV curing has been recognized as that the UV radiation is probably the one of the most efficient methods of hardening, coating, and adhesives. Among other projects that we have to develop, we have the QIKcap technology that is done by HAI Solutions. This is a product with a single-use cap for intravenous access points, and the product was very recently approved by the Food and Drug Administration, FDA, in the U.S. Intellego is a shareholder of HAI, and Intellego has also the exclusive right to market and sell this product, QIKcap, in the China market. The product, QIKcap, which will soon be finished, will be presented at trade fairs in this spring and early summer in the U.S., but also in Spain, in Valencia. There is also another market opportunity, and that is to work hand in hand with the producers of UVC hardware, those who make the robots and towers, as a validation tool from the manufacturing side. Together with the new board, coming weeks, we will discuss which way we best go forward on these projects. We also believe that there are other applications of our patented ink in the future. We will look into that as well. In parallel to this, we will also work on our internal side, on the sales side, and try to develop a strong sales spirit, where we want to focus on finding active distribution partners in different regions globally. The aim is that we can then train and support partners in reaching out to large numbers of hospitals and help them implement routines for the frequency of usage of dosimeters. To sum it all up, what we have today is a much smaller business than before November. However, we still believe in the Intellego's photochromic ink and the role it can play in the market of UV disinfection through the dosimeters, and also other application areas for the patented ink. Now, I'd like to hand over the word back to Greg Batcheller. Okay. Thank you, gentlemen. I think this is a very important report. And as I said, there is a possibility on your screens for you to ask us questions by email, which we will answer by email. In the meantime, I can say we look forward to seeing many of you at the shareholder meeting in Stockholm on Monday. And with that, I close this meeting. Thank you very much.